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Abstract We compare the efficacy including spirometry, peakexpiratory flow (PEFR) and qualityof life and safetyof
an 8-week treatmentwithinhaledoxitropium, theophylline or theircombinationinpatientswithmild-to-severs chronic
obstructivepulmonarydisease (COPD).We conducted amulticentre, double-blind, double-dummy, randomized, paral-
lel-group studyat 29 Italianoutpatients clinics.Agroup of 236 patientswithmild-to-severe COPD (baseline FEV1,r70%
of predicted value) were recruited.Treatmentswere as follows: Inhaled oxitropiumbromide 200 mg (N=75), sustained-
release oraltheophylline 300mg (N=81) or theircombination (N=80), takentwice daily.Spirometry (FEV1and FVC)was
evaluatedevery 4weeks, andmorningandevening PEFR (before and 2--4 h afterdrugintake)wasmeasureddaily. Symp-
toms, cough and dysponea, were recorded daily.Health status was evaluated at baseline and week 8 using the disease
specific St George’s Respiratory Questionnaire (SGRQ).Any adverse eventoccurring during the treatment periodwas
recorded on a diary card.FEV1and FVC improved in all the groups at 4 and 8 weeks, but the difference between treat-
mentgroups did not reach statistically significant levels.Differences between groups in pre-dosingmorning and evening
PEFRwere not significant. Post-dosingmorning and evening PEFRwere increased and the largest increase was seen in
patients treatedwithbothdrugs.However, differencesbetweengroupswas significantonly foreveningvalues (P=0.008).
The proportion of patients who experienced a decrease in symptoms was high in all groups but no differences among
groupswereobserved.SGRQ totalscoresdecreasedin alltreatmentgroups after 8weeks, particularlyintheoxitropium
and combination groups.Clinically, significant change (4 units) was only observed in patients treated with oxitropium
bromidewhether with or withouttheophylline. Adverse events related to treatmentswere higher in the group treated
with theophylline alone (Po0.02).We conclude that inhaled oxitropiumbromide alonewas associatedwith an improve-
ment in FEV1,PEFR and symptomsinpatientswith COPD thatwasnot statisticallydifferent fromthatoforaltheophylline
alone or of the combination of both drugs.Oxitropium bromide in combination with theophylline provided a greater
improvement in evening post-dosing PEFR.Oxitropium bromide alone or in combination with theophylline improved
the qualityof life better thantheophylline alone.r2002 Elsevier Science Ltd.Allrights reserved
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Chronic obstructivepulmonarydisease (COPD) is a con-
dition characterized by air£ow limitation cough, mucus
hypersecretion, which is progressive and leads to
dysponea and impaired alveolar^arterial gas exchange
(1,2). The severe air£ow limitation and progressive
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activity and quality of life (1,2). Inhaled or oral bronchodi-
lators are recommended as symptomatic treatment of
patients with stable COPD (1,2).
Inhaled anticholinergics, b2-selective agonists, and
oral xanthines have shown to signi¢cantly improve pul-
monary function and clinical status in patients with
COPD (3,4). Improvement in health status (quality of life)
has been documented with some bronchodilators but
only after long-term treatment (5).
Guidelines recommend the use of more than one
bronchodilator for the treatmentof COPDpatientswith
moderate and severe disease (ERS, ATS, BTS guidelines).
The bronchodilator e¡ect of combined treatment with
theophyllines and b2-agonists vs. each drug administered
alone has also been widely investigated in COPD pa-
tients. However, the superior clinical bene¢t provided
by a combined treatment with these two drugs is still
controversial: some studieshave demonstrated that they
have an additive e¡ect (6^8), whereas others could not
con¢rm this ¢nding (7,9).Both b2-agonists and theophyl-
lines have cardiovascular side-e¡ects whose severity can
be potentiated when used in combination (10). Such car-
diovascular e¡ects may be even more severe in the el-
derly COPD patients showing an impaired heart
function (11).
In COPD patients, anticholinergics have proved to be
at least as potentbronchodilators as b2-agonists (12) and
more potent than theophylline (4,13). Anticholinergics
together with b2 agonists, represent the ¢rst line
bronchodilator treatmentofCOPD (1,2). A large propor-
tion of COPD patients are treated with more than
one bronchodilator and in countries where theophylline
use is low, the most common combination is with
b2-agonists (14,15). The e⁄cacy and safety of the
combination of anticholinergics and b2-agonists is
well established (16). In contrast, e⁄cacy and safety
data on anticholinergics when given in combination with
oral xanthines is sparse and is limited to short-term
treatment (13,17 2^9)
Oxitropium bromide is a quaternary anticholinergic
agent, with a longer duration of action than ipratropium,
which has been shown to last up to12h.Because of their
di⁄culty in passing throughmembranes, quaternary am-
monium compounds are characterized by very low en-
teric absorption and inability to cross the blood^brain
barrier and systemic e¡ects are very seldom reported
(20,21).The clinical e⁄cacy and safety of oxitropium bro-
mide when given together with theophylline has never
been investigated.
The purpose of this study is to investigate the e⁄cacy
and safety of 8-week treatmentwith inhaled oxitropium
bromide (100mcg/pu¡, 2 pu¡s b.i.d. = 400mcg daily) and
sustained-release anhydrous theophylline (300mg orally,
b.i.d.) when given alone and in combination in patients
withmild-to-severe COPD.MATERIALSANDMETHODS
Patient population
Patients, who had a clinical history of COPD as de¢ned
by the AmericanThoracic Society (1), were current or
ex-smokers, between 35 and 80 years of age andbaseline
FEV170% of predicted valuewere included in the study.
Patients with a daily PEFRvariability20% and a change
in FEV1 after 200mg fenoterol420% of predicted value
and total lung capacity (TLC) 70% of predicted value
were excluded.Other exclusion criteria were: acute air-
ways infection during the preceding 4 weeks; blood eo-
sinophilia48%; history of asthma, allergic rhinitis, cystic
¢brosis and any atopic disease; peptic ulcer and liver, kid-
neyor heart failure.None of thepatientswas taking oral
steroids during 1 week preceding the study. Patients
were also required to demonstrate theophylline plasma
levels between 8 and 20mg/ml at the end of the run-in
period when they were treated with sustained-release
theophylline 300mg b.i.d.
Study design
The study was conducted in 29 out-patient centres and
followed a double-blind, double-dummy, randomized,
parallel group design.The study was performed accord-
ing to the Helsinki Declaration and the European Com-
munity GCP Guidelines. The protocol was approved by
the Ethics Committees within each participating centre
and informed consentwas signed by each patient.
Screening phase. Patients who met inclusion/exclusion
criteria entered a 1-week screening phase. During this
week, they were instructed to discontinue treatment
with anticholinergics, chromones, and inhaled corticos-
teroids.These drugs were not allowed during the whole
duration of the study. Inhaled short-acting b2-agonists
were allowed as rescue medication. Patients underwent
a detailed physical examination and a complete medical
history was recorded. Patients were also asked to mea-
sure daily PEFR values, symptom scores cough and dys-
ponea, any adverse events and concomitant
medications. On the last day of the screening phase, a
spirometric testing was performed and FEV1, FVC1 and
TLC were measured. This was followed by the assess-
ment of bronchial reversibility to inhaled fenoterol
200mg.
Run-in phase. At the end of the screening phase, eligi-
ble patients were treated with sustained-release anhy-
drous theophylline (300mg orally, b.i.d.) plus oxitropium
bromide placebo (200mg, b.i.d.) for 3^6 days. At the end
of the run-in phase, plasma theophylline levels were as-
sessed between 3 and 5h after the last intake.Only pa-
tients whose theophylline plasma levels ranged between
8 and 20mg/mlwererandomized. Atrandomization, vital
signs and routine laboratory tests were assessed.
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signed to receive for a period of 8 weeks, one of the fol-
lowing treatments: (1) inhaled oxitropium bromide
200mg b.i.d. plus sustained-release capsules of theophyl-
line 300mgb.i.d.; (2) placebo of oxitropiumbromideplus
sustained-release capsules of theophylline 300mg b.i.d.;
(3) inhaled oxitropium bromide 200mg b.i.d. plus theo-
phylline placebo capsules. Each patient took two pu¡s
or inhaled treatment and one capsule of oral treatment,
in the morning at 8.00 a.m. and in the evening at 8.00
p.m. Patients were assigned to treatment group accord-
ing to a pre-determined randomization list in blocks of
six patients. During the treatment phase, visits to the
study clinic were scheduled every 4 weeks. At each visit,
clinical examination and vital signs were recorded and
spirometric measurements were performed during
post-drug treatment. At the end of the study, all blood
tests were repeated. Throughout the study period, all
adverse events were recorded on a daily diary card.
Diary card assessments
During the study phase, patients recordedmorning and
evening PEFR, symptom scores, rescue medications and
any adverse event on a daily diary card. PEFR measure-
ments were performed four times daily: in the morning
and in the evening, immediately before and 2^4h after
drug intake. On each occasion, patients were asked to
measure PEFR three times and to record the highest
PEFRvalue. Baseline PEFRvalues were obtained by aver-
aging individualmorning and eveningmeasurements dur-
ing the1week screening phase.
Cough and dysponea were assessed daily and scored
as: 1=none, 2=mild, 3=moderate, 4=marked, 5=severe;
cough frequency: 1=none, 2=rare, 3=occasional, 4=fre-
quent, 5=almost constant. Symptom scores were ex-
pressed as the mean of weekly scores. End-study
symptoms have been classi¢ed as ‘‘improved’’ when ¢nal
score was lower than initial score, otherwise have been
classi¢ed as ‘‘worsened’’. The number of rescue medica-
tion, namely inhaled short-acting bronchodilators, was
also recorded daily.
Quality of life assessment
Health status was evaluated by administering the ‘‘St
George’s Respiratory Questionnaire’’, using a validated
Italian version.The SGRQ is a disease-speci¢c self-admi-
nistered questionnaire and assesses three domains of
subjective health status in COPD patients: activity, im-
pact and symptoms. Evaluation was performed at
screening and at ¢nal visit. An improvement is reported
as a decrease from baseline. Scores are calculated for
each of the individual domains and are combined to
obtain a global score which is used to classify a clinicallysigni¢cant improvement in health status de¢ned as a 4-
point decrease from baseline (22).
Statistical analysis
Statistical analysis was performed by means of one-way
or repeated-measures ANOVA followed, where neces-
sary, by multiple comparisons.To estimate missing data,
the last observation carried forward (LOCF) procedure
was used. Frequency was tested using contingency ta-
bles.The one-way ANOVAwas replaced by t-test when
appropriate. Data from SGRQ in all treatment groups
were examined by the analysis of covariance (ANCOVA)
in which the change in SGRQ scores was the dependent
variable. The independent variables were treatment
groups and baseline SGRQ score. A decrease of 4 units
is SGRQwas regarded as a‘‘clinically signi¢cant improve-
ment’’.Post hoc analysis comparing treatmentgroupswas
performed using Fisher PLSD.Univariate analysis of the
changes in SGRQ scoreswas performedusing t-tests. All
analyses were two-sided and were carried out by SAS
(version 6.12 for WINDOWS’95). A P-value o0.05 was
considered as statistically signi¢cant.
RESULTS
Patients
A group of 288 patients with COPD were enrolled be-
tween February 1996 and December 1997 and a group
of 236 patients were randomized to: (1) oxitropium bro-
mide plus theophylline (n=75); (2) placebo of oxitropium
bromide plus theophylline (n=81); (3) oxitropium bro-
mide plus theophylline (n=80). A group of 230 patients
provided su⁄cient information for the intention-to-
treat analysis, and a total of 182 patients successfully
completed the study. A group of 34, out of 236 rando-
mized patients, discontinued the study but no di¡erence
inwithdrawal distribution (number andreason) between
treatment groups was observed (Table 1). Patients
characteristics are shown in Table 1. Treatment groups
were well matched. Bronchodilator response to
inhaled fenoterol demonstrated that 73% of
randomized patients did not show any signi¢cant
reversibility whereas FEV1 increased more than 15%
and more than 200ml from baseline, in only 27% of
them. Since there were no statistically signi¢cant di¡er-
ences between intention to treat and per-protocol
groups, the results from the intention-to-treat analysis
are reported.
Lung function anddaily PEFRvariability
Baseline FEV1 and FVC values in the three treatment
groups were not di¡erent. An increase in FEV1and FVC,
both as absolute values and % change frombaseline, was
TABLE 1. Demographic andbaseline characteristics of randomizedpatients.Values aremean7SEM
Oxitropiumb. plus theophylline (n=75) Theophylline (n=81) Oxitropiumb. (n=80)
Gender (M/F) 64/11 65/13 71/9
Age (years) 64.471.0 65.371.0 63.971.0
Height (cm) 165.570.7 165.571.0 165.770.8
Ex-smokers (n; %) 61 (81%) 66 (81%) 67 (84%)
Current smokers (n; %) 14 (19%) 15 (19%) 13 (16%)
Daily PEFRvariability (%) 10.270.5 11.870.5 11.770.5
TLC (l) 6.2270.15 6.2270.16 6.4570.16
TLC (% predicted) 103.372.0 103.872.2 106.572.2
FVC (l) 2.4470.07 2.4270.09 2.4970.08
FEV1 (l) 1.3770.05 1.3770.05 1.3470.05
FEV1 (% predicted) 50.9871.54 51.4571.59 48.9371.41
FEV1increase after fenoterol (%) 6.0970.44 6.8670.55 6.8970.48
Withdrawals
Diseaseworsened 1 0 1
Adverse events 3 4 2
Ine⁄cacy 1 2 3
Notcompliantwith protocol 1 1 2
Lostto follow-up 1 2 0
Consentwithdrawal 3 2 1
Protocolviolation 2 1 1
Total 12 12 10
884 RESPIRATORYMEDICINEobserved in all three groups being more marked in the
combination than in the theophylline and oxitropium
groups at 4^8weeks (Table 2).No statistically signi¢cant
di¡erence between groups was observed.
Mean PEFR values recorded before and after drug in-
take (morning and evening) at baseline and after 8 weeks
are given in Table 3. The morning and evening baseline
pre-dosing PEFR showed very little change at week 8 in
all three treatment groups. In contrast, the morning
post-dosing PEFRmarkedly increased in all three groups,
particularly in the combination group. In the combina-
tion group, the evening post-dosing PEFR change was
higher than in the other two groups.No statistically sig-
ni¢cant di¡erence was observed between treatment
groups for either morning or evening post-dosing PEFR
change.
Time course of weekly changes in PEFR as percent of
baselinevalues are shown in Fig1. Inpatients treatedwith
oxitropium b. plus theophylline, changes in morning and
evening PEFR pre-dosing tended to be higher, although
not signi¢cantly, compared to changes found in patients
with either theophylline or oxitropium b. alone.This in-
crease in PEFR was evident after 1-week treatment and
remain constant throughout the study period (Fig.1). At
all time points, di¡erences among groups in pre-dosing
values were not signi¢cant. An increase in post-dosing
PEFRwas evident both in the morning and the evening,
the largest increasewas observed in the group receiving
both active drugs. However, di¡erences between treat-ments were statistically signi¢cant only for evening
post-dosing change (P=0.008) (Fig.1).
Symptoms anduse ofrescuebronchodilators
At baseline, symptom scores for cough and dysponea in
the three treatment groups were similar. In addition, the
proportions of patients exhibiting decreased symptom
intensity score at the end of treatment with both drugs,
theophylline or oxitropium b, were respectively: 77.8,
79.2 and 81.8% for cough frequency; 81.9, 81.8 and 83.1%
for cough intensity; 83.3, 84.4 and 84.4% for dyspnoea.
Di¡erences among groups were not signi¢cant. Use of
rescue inhaled bronchodilators was similar in all three
treatment groups (19.2, 17.9 and 26.6% in the oxitropium
b. plus theophylline, theophylline and oxitropium b.
groups, respectively).
Quality of life
The St George’s Respiratory Questionnaire (SGRQ) was
completed at baseline and after 8 weeks of treatmentby
207 patients (67 patients of oxitropium b. plus theophyl-
line group, 69 patients of theophylline group and 71 pa-
tients of oxitropium group). Total score decreased in all
groups and the change was statistically signi¢cant com-
pared to baseline (Po0.0015, o0.001 and o0.0001, re-
spectively). However, the decrease in total score
TABLE 2. Spirometry at baseline and during treatment.Values aremean7SEM
Oxitropiumb. plus theophylline (n=73) Theophylline (n=78) Oxitropiumb. (n=79)
FEV1 (l)
Baseline 1.3770.05 1.3770.05 1.3470.05
Week 4 1.5570.06 1.4070.07 1.3970.06
Week 8 1.5070.07 1.4370.07 1.3970.07
Change atweek (n) 0.1670.04 (68) 0.0470.03 (75) 0.0570.03 (72)
Change atweek 8 (n) 0.1170.05 (64) 0.0670.03 (71) 0.0470.04 (72)
FVC (l)
Baseline 2.4470.07 2.4270.09 2.4970.08
Day 28 2.6070.09 2.4370.10 2.5570.09
Day 56 2.5870.09 2.4770.10 2.5470.09
Change atweek 4 (n) 0.1370.05 (68) 0.0570.05 (75) 0.0470.04 (77)
Change atweek 8 (n) 0.1270.07 (64) 0.0570.05 (71) 0.0170.05 (72)
TABLE 3. Baseline PEFRvalues in l/min andpercentchange after treatment in each group.Values aremean7SD
Oxitropiumb. plus theophylline (N=73) Theophylline (N=78) Oxitropiumb. (N=7)
Morningpre-dosing
Baseline 271.378.8 277.1711.3 257.8710.0
After 8 weeks 281.2710.3 276.0712.0 256.0710.4
% Change 9.974.9 1.074.7 1.875.6
Morningpost-dosing
Baseline 271.378.8 277.1711.3 257.8710.0
After 8 weeks 295.4724.2 295.6718.5 275.4710.7
% Change 24.274.8 18.574.8 17.675.9
Eveningpre-dosing
Baseline 275.478.6 283.0711.5 262.9710.4
After 8 weeks 285.5710.2 284.8712.0 265.4710.3
% Change 10.174.7 1.874.5 2.575.6
Eveningpost-dosing
Baseline 275.478.6 281.7711.5 264.8710.3
After 8 weeks 294.9710.2 286.5711.8 272.5710.4
% Change 19.574.8 4.774.9 7.775.2
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treated with both oxitropium whether alone (4.071.1
units) or in combinationwith theophylline (4.771.1 units)
(Fig. 2). The decrease was mainly due to changes in the
activity and impact scores (Fig. 2). The di¡erences be-
tween treatments were not statistically signi¢cant.
Safety
During randomized treatments, no clinically relevant
changes in haematology, clinical chemistry tests and vital
signswerereported.Overall, 73 patients reportedor ex-
hibited a total of 135 events.The most frequent adverse
events were: epigastric pain (¢ve events) in the oxitro-
pium b. + theophylline group and COPD exacerbation
in the theophylline (¢ve events) and oxitropium group(nine events). The main features events classi¢ed as
drug-related are summarized inTable 4.The proportion
of patients reporting treatment-related adverse events
(Po0.02) and gastrointestinal treatment-related adverse
events (Po0.04) in the theophylline group was signi¢-
cantly greater than that found in oxitropium+ theophyl-
line and oxitropium group.Overall ¢ve patients treated
with oxitropium alone, and two patients treated with
theophylline alone, exhibited adverse events that have
been classi¢ed as serious, resulting in hospitalization. In
all patients but one treated with theophylline, the study
medication was withdrawn.The reasons for hospitaliza-
tion included: exacerbation of COPD (threepatients; one
patient exhibited concurrent atrial arrhythmia); consti-
pationwith abdominal pain; low-back pain due to pre-ex-
istent osteoarthritis; transient cerebral ischaemic attack
with pre-existent hypercholesterolaemia. All events
FIG. 1. Time course of the changes in meanweekly PEFR from pre-study (Mean7SEM) during treatment with oxitropium alone,
theophylline alone or bothtreatments in combination.
FIG. 2. Changes frombaseline in SGRQ total score, symptoms score, activity score and impacts score.
886 RESPIRATORYMEDICINEhave been classi¢ed as having doubtful correlation with
the study medication, except for constipation and ar-
rhythmia, both events occurring under theophylline
treatment and classi¢ed as having possible relationship.DISCUSSION
To our knowledge, this study is the largest study compar-
ing the e¡ect of prolonged treatment with an anticholi-





Patientswith adverse drugreactions 7 (9.3%) 16 (20.3%)** 5 (6.3%)
Gastrointestinal 10 22* 3
Nervous 4 9 3
Skin F 3 F
Cardiovascular, rhythmdisorders F 3 1
Other 1 2 F
Total drug-related events 15 39 7
*Po0.02 and **Po0.04 bycomparisonwith oxitropiumb. plus theophylline group and oxitropiumb. group.
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combination in COPD patients with a wide-range dis-
ease severity (2). The results of this study show that in
COPD patients, with relatively poor airway reversibility,
the combination of inhaled oxitropium bromide and oral
xanthine has only amarginally greater therapeutic e¡ect
in comparison with either xanthine alone or oxitropium
bromide alone. The better therapeutic e⁄cacy of com-
bined treatment is supported by the improvement in
post-dosing PEFR.
It is not surprising that in a COPD populationwith re-
latively poor reversibility no signi¢cant improvement in
lung function parameters could be demonstrated with
oxitropium, theophylline and the combination. In pa-
tientswithpoor airwayreversibility small changes in lung
function can have a signi¢cant clinical impact on symp-
toms and exercise tolerance (23 2^7). It is therefore not
surprising that themodestchanges in lung function para-
meters observed with all treatments remarkably im-
proved respiratory symptoms inmost patients.
We found that changes in lung function and in PEFR
variability during treatments were small and only mar-
ginally in favour of the combined treatment. Interest-
ingly, no clear di¡erences were also detected when
patients were grouped according to the degree of base-
line air£ow obstruction. The absence of a well de¢ned
and more marked improvement in lung function and
PEFR in those patients showing a more severe sever air-
way obstruction suggests that these parameters are un-
likely to predict a better functional response to
bronchodilator therapy in patients with COPD. It has
previously been reported that short acting b2-broncho-
dilators, namely salbutamol (7,27) and terbutaline (28)
when added to oral xantines produce a better ‘‘clinical
e¡ect’’ thanwhen given alone.However, these studies al-
ways included a placebo group and although di¡erences
in lung function among treatment groups were signi¢-
cant, changes were small (7,27) and sometimes absent
(28).Very few studies have examined the di¡erences be-
tween treatmentswith xantines or ipratropium alone or
in combination. It has been observed that the combinedtreatment with ipratropium bromide and oral theophyl-
line may produce a signi¢cantly greater bronchodilata-
tion than either treatment alone (29).
Several factors may explain di¡erences among di¡er-
ent studies. These include: (1) presence of a placebo
group; (2) study design; (3) di¡erent doses; (4) di¡erent
populations and (5) di¡erent outcomemeasures. Indeed
the absence of a placebo group may have highly in£u-
enced the results of our study. It is of interest that most
studies showing a di¡erence between combined therapy
and bronchodilator therapy alone include a placebo
group. In addition, several studies have been conducted
following a cross-over design, without a wash-out peri-
od.Thus, a carry over e¡ect of treatments cannot be ex-
cluded.Weused standard doses of both theophylline and
oxitropium. It is likely that di¡erent results could be ob-
tained by increasing the doses of either drug. However,
results from these studies are likely to be of little clinical
relevance since also the incidence of side e¡ect is likely to
increase.We randomly selected a large group of COPD
patientswith awide degree of airwayobstruction as sug-
gested by baseline FEV1. It appears that our population
represents remarkably well the AmericanThoracic So-
ciety criteria for COPD, since approximately 30% of
them showeda signi¢cantreversibilityof airway obstruc-
tion (1), i.e. they have an asthmatic obstructive compo-
nent. In COPD patients, the e¡ects of treatments have
been so far mostly assessed by changes in lung function
such as FVC, FEV1 and PEFR. However, it is likely that
other lung function parameters would be more appro-
priate to detect di¡erences in response to bronchial ac-
tive treatments in COPD patients. Interestingly, it has
been recently reported that changes in IC or FRC after
a bronchodilator better re£ect the clinical bene¢t asso-
ciated with the administration of these drugs in COPD
(31 3^2).
We found that symptoms decreased in all treatment
groups.Our results are in agreement with previous stu-
dieswhich examined the e¡ectof inhaledbronchodilator
alone or in combination with xantines (7,27). A variable
degree of changes in symptoms has been reported in
888 RESPIRATORYMEDICINECOPD patients treated with xantines alone: some stu-
dies could not demonstrate any signi¢cant changes
(8,27), whereas others found a clinically relevant im-
provement (7,33). Discrepancies could be explained by
the di¡erent severity of the disease in di¡erent popula-
tions, by the duration of xanthine administration, and
by di¡erences in the de¢nition of ‘‘improvement/dete-
rioration’’.
This is the ¢rst study in which quality of life has been
assessed during treatment with oxitropium bromide.
The improvement in SGRQ total score for oxitropium
containing groups, is close to that foundwith salmeterol
in a larger population of COPD patients showing almost
identical clinical characteristics and over a longer treat-
ment period (16 weeks treatment) (5). In addition, it
shouldbeunderlined that theophylline alone didnothave
any clinically signi¢cant e¡ect on quality of life. Since
both activity and impact scores clinically improved in
the oxitropium groups, it seems to suggest that this
could partly be due to improvement in exercise perfor-
mance. Interestingly, it has been recently demonstrated
that oxitropiumbromide signi¢cantly increases the cycle
endurance time in patients with COPD (34). Although a
similar increase in exercise performance has also been
reported during treatment with theophylline (30), the
absence of changes in SGRQ scores during treatment
with theophylline might be linked to a higher incidence,
in our population, of drug-related side-e¡ects. A similar
trend has been reported when the salmeterol dose has
been increased (5).
An interesting observation emerged from our study.
We observed that the combination treatmentwas asso-
ciated with a signi¢cantly lower incidence of adverse re-
actions compared to theophylline alone. It is tempting to
hypothesize that this e¡ectmightbe due to a decrease in
the incidence of gastrointestinal adverse drug reactions.
Although patients treated with the combination re-
ceived the same amount of theophylline as those who
had theophylline alone, the incidence of gastro-intestinal
drug reactions was half of that found during treatment
with theophylline alone. It is possible that the amount of
oxitropiumbromidewhich is swallowed following the in-
halation,mayexert a protective e¡ect againstgastric re-
actions associated with theophylline intake. Indeed,
muscarinic receptor antagonists such as pirenzepine
are in use as anti-ulcer treatments with favourable
results (35).
In conclusion, the present study suggests that inhaled
oxitropium bromide alone was associated with an im-
provement in PEFR and symptoms in patients with
COPD that was not substantially di¡erent from that of
oral theophylline alone or of the combination of both
drugs.However, oxitropium bromide alone or in combi-
nationwith theophylline provided a better improvement
in the quality of life than theophylline alone as well as a
better safety pro¢le.Acknowledgements
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